Abstract 4103
Background
Obesity is an established risk factor for colorectal cancer (CRC), however little is known about the impact on survival of changes in body composition during chemotherapy.
Methods
A prospective study of adult CRC patients undergoing chemotherapy between 2012-2016 was conducted. Baseline body composition and longitudinal changes were examined using computed tomography (CT) images at two timepoints (interval 7 months, IQR:5-9 months) using paired t-tests. Sarcopenia and low muscle attenuation (MA) were defined using published cut-offs. Cox models were used to estimate mortality hazard ratios, adjusted for known prognostic covariates –age, sex, performance status & systemic inflammation.
Results
In total, 268 patients were recruited (66% male, mean age 63 years) and 51% were undergoing chemotherapy with a palliative intent. At baseline, 4% had BMI <20 kg/m2 & 58% had BMI ≥25 kg/m2. However, 38%, 34% & 43% had cachexia, sarcopenia & low MA, respectively. Over 100 days, 68% were muscle stable (±1 kg), while 25% lost >1 kg and 7% gained >1 kg. Fat mass remained stable ±1 kg in 49%, while 28% lost >1 kg and 23% gained >1 kg. On multivariate analysis, baseline BMI and subcutaneous fat (SAT) loss predicted survival in patients treated with palliative intent. Normal BMI (20-25kg/m2) predicted reduced survival compared to overweight (25-30kg/m2) [HR:1.80 (95% CI:1.04–3.14), p = 0.037]. Loss of > 6.4% SAT over 100 days was predictive of poor survival versus gain/<6.4% loss, independent of changes in muscle mass [HR:2.2 (95% CI:1.07–4.62), p = 0.033].
Conclusions
Patients with CRC experience significant losses in muscle and fat mass during chemotherapy. Loss of SAT mass during palliative chemotherapy is prognostic of poor survival, independent of changes in muscle mass. Baseline BMI in the overweight range confers a survival advantage. Nutritional strategies to prevent or attenuate weight loss during chemotherapy are advisable especially in the context of advanced CRC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Breakthrough Cancer Research.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5747 - The routine use of sentinel lymph node biopsy in high risk DCIS lesions is not justified
Presenter: Fanny Preat
Session: Poster Display session 2
Resources:
Abstract
1837 - Oncological impact of re-excision for positive margin status after breast conserving surgery in invasive breast cancer
Presenter: Kenjiro Jimbo
Session: Poster Display session 2
Resources:
Abstract
4347 - Pneumonitis and fibrosis after breast cancer radiation.
Presenter: Jarle Karlsen
Session: Poster Display session 2
Resources:
Abstract
2280 - Prognosis of mastectomy with reconstruction after neoadjuvant chemotherapy: a nationwide study in Korean Breast Cancer Society
Presenter: Sungmin Park
Session: Poster Display session 2
Resources:
Abstract
804 - A negative prognosis of radiotherapy-induced lower lymphocyte to monocyte ratio in patients with breast cancer
Presenter: Chang-ik Yoon
Session: Poster Display session 2
Resources:
Abstract
2701 - Patient data to monitor clinical patterns in early and advanced breast cancer in Europe
Presenter: Francesco Giusti
Session: Poster Display session 2
Resources:
Abstract
1437 - A critical appraisal of quality indicators of breast cancer treatment in Belgium
Presenter: Didier Verhoeven
Session: Poster Display session 2
Resources:
Abstract
1534 - Predictors of adherence among post-menopausal women receiving adjuvant endocrine therapy for breast cancer in Ontario, Canada
Presenter: Phillip Blanchette
Session: Poster Display session 2
Resources:
Abstract
4363 - Evaluation of endocrine therapy and patients preferences in early breast cancer: results of Elena study
Presenter: Emilia Montagna
Session: Poster Display session 2
Resources:
Abstract
2679 - Baseline Quality of life (QoL) and chemotherapy related toxicities (CRT) in localized breast cancer (BC) patients (pts): the French multicentric prospective CANTO cohort study
Presenter: Idlir Licaj
Session: Poster Display session 2
Resources:
Abstract